XENE

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Xenon Pharmaceuticals Inc

NASDAQ | XENE

36.70

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 17, 2025)

$2.75B

Market Cap

-

P/E Ratio

-3.55

EPS

$46.00

52 Week High

$26.74

52 Week Low

HEALTHCARE

Sector

XENE Chart

Recent Chart
Price Action

XENE Technicals

Tags:

XENE Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$2.6M
Total Revenue $0
Cost Of Revenue $2.6M
Costof Goods And Services Sold $2.6M
Operating Income -$279M
Selling General And Administrative $69M
Research And Development $210M
Operating Expenses $277M
Investment Income Net -
Net Interest Income $42M
Interest Income $42M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.6M
Income Before Tax -$238M
Income Tax Expense -$4.1M
Interest And Debt Expense -
Net Income From Continuing Operations -$234M
Comprehensive Income Net Of Tax -
Ebit -$238M
Ebitda -$236M
Net Income -$234M

Revenue & Profitability

Earnings Performance

XENE Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $798M
Total Current Assets $635M
Cash And Cash Equivalents At Carrying Value $143M
Cash And Short Term Investments $143M
Inventory -
Current Net Receivables $1.5M
Total Non Current Assets $163M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $127M
Short Term Investments $484M
Other Current Assets $6.9M
Other Non Current Assets -
Total Liabilities $43M
Total Current Liabilities $36M
Current Accounts Payable $5.1M
Deferred Revenue -
Current Debt -
Short Term Debt $10M
Total Non Current Liabilities $7.6M
Capital Lease Obligations $9M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $9M
Other Current Liabilities $14M
Other Non Current Liabilities -
Total Shareholder Equity $755M
Treasury Stock -
Retained Earnings -$899M
Common Stock $1.5B
Common Stock Shares Outstanding $78M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$181M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.6M
Capital Expenditures $3.1M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $165M
Cashflow From Financing $12M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$234M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$2.6M
Total Revenue $0
Cost Of Revenue $2.6M
Costof Goods And Services Sold $2.6M
Operating Income -$279M
Selling General And Administrative $69M
Research And Development $210M
Operating Expenses $277M
Investment Income Net -
Net Interest Income $42M
Interest Income $42M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.6M
Income Before Tax -$238M
Income Tax Expense -$4.1M
Interest And Debt Expense -
Net Income From Continuing Operations -$234M
Comprehensive Income Net Of Tax -
Ebit -$238M
Ebitda -$236M
Net Income -$234M

XENE News

XENE Profile

Xenon Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing innovative therapies for patients with neurological disorders. With a robust pipeline of drug candidates, Xenon employs advanced technologies to target genetic and rare conditions, aiming to transform patient care. The company’s commitment to scientific excellence and patient outcomes positions it as a key player in the biopharmaceutical landscape, catering to both national and international markets.

ATCH
+84.47%
$1.59
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.16%
$7.98
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
KDLY
+20.96%
$1.50
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+29.01%
$2.49
LYT
-16.77%
$0.09
JOBY
-1.59%
$14.16
BTG
+0.46%
$4.34
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
UBER
-4.95%
$92.98
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
PFE
+0.56%
$24.03
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
WULF
+3.93%
$11.37
OPI
-31.80%
$0.56
RELI
+6.58%
$0.72
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
NOK
+1.84%
$4.69
GOOGL
-0.64%
$249.53
CIFR
+7.55%
$12.38
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
AMZN
-1.40%
$230.76
JD
+1.52%
$35.24
ATYR
-5.09%
$1.02
QUBT
+5.21%
$17.75
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
DVLT
-21.32%
$0.35
FAAS
-8.85%
$0.08
BABA
+2.39%
$166.09
HOOD
+1.23%
$118.82
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
CLSK
+2.14%
$11.44
JBLU
0.00%
$5.07
BURU
-0.93%
$0.13
HIMS
-1.08%
$50.34
ETWO
0.00%
$3.30
CAN
+0.23%
$0.80
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
IONZ
-10.28%
$4.80
ATCH
+84.47%
$1.59
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.16%
$7.98
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
KDLY
+20.96%
$1.50
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+29.01%
$2.49
LYT
-16.77%
$0.09
JOBY
-1.59%
$14.16
BTG
+0.46%
$4.34
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
UBER
-4.95%
$92.98
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
PFE
+0.56%
$24.03
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
WULF
+3.93%
$11.37
OPI
-31.80%
$0.56
RELI
+6.58%
$0.72
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
NOK
+1.84%
$4.69
GOOGL
-0.64%
$249.53
CIFR
+7.55%
$12.38
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
AMZN
-1.40%
$230.76
JD
+1.52%
$35.24
ATYR
-5.09%
$1.02
QUBT
+5.21%
$17.75
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
DVLT
-21.32%
$0.35
FAAS
-8.85%
$0.08
BABA
+2.39%
$166.09
HOOD
+1.23%
$118.82
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
CLSK
+2.14%
$11.44
JBLU
0.00%
$5.07
BURU
-0.93%
$0.13
HIMS
-1.08%
$50.34
ETWO
0.00%
$3.30
CAN
+0.23%
$0.80
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
IONZ
-10.28%
$4.80
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.